T. Rowe Price Associates’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $53K | Buy |
|
|||||
|
2025
Q1 | $31K | Hold |
|
|||||
|
2024
Q4 | $63K | Sell |
|
|||||
|
2024
Q3 | $229K | Hold |
|
|||||
|
2024
Q2 | $214K | Sell |
|
|||||
|
2024
Q1 | $2.01M | Buy |
|
|||||
|
2023
Q4 | $204K | Sell |
|
|||||
|
2023
Q3 | $2.07M | Buy |
|
|||||
|
2023
Q2 | $4.58M | Sell |
|
|||||
|
2023
Q1 | $8.55M | Sell |
|
|||||
|
2022
Q4 | $26.8M | Sell |
|
|||||
|
2022
Q3 | $70.4M | Sell |
|
|||||
|
2022
Q2 | $123M | Buy |
|
|||||
|
2022
Q1 | $190M | Buy |
|
|||||
|
2021
Q4 | $230M | Sell |
|
|||||
|
2021
Q3 | $235M | Buy |
|
|||||
|
2021
Q2 | $270M | Sell |
|
|||||
|
2021
Q1 | $260M | Sell |
|
|||||
|
2020
Q4 | $319M | Buy |
|
|||||
|
2020
Q3 | $93.4M | Buy |
|
|||||
|
2020
Q2 | $43.3M | Buy |
|
|||||
|
2020
Q1 | $19.5M | Sell |
|
|||||
|
2019
Q4 | $19.2M | Sell |
|
|||||
|
2019
Q3 | $18.5M | Buy |
|
|||||
|
2019
Q2 | $24.1M | Sell |
|
|||||
|
2019
Q1 | $21.9M | Buy |
|
|||||
|
2018
Q4 | $11.8M | Buy |
|
|||||
|
2018
Q3 | $13.2M | Buy |
|
|||||
|
2018
Q2 | $8.95M | Sell |
|
|||||
|
2018
Q1 | $9.4M | Buy |
|
|||||
|
2017
Q4 | $3.21M | Buy |
|